falsefalse

Lower-Risk MDS: Current and Future Treatment Strategies - Episode 5

Recent Updates for Second-Line Treatment Options in Lower-Risk MDS

, ,

The panel of experts review recent data updates for new agents being investigated in the second line in patients with lower-risk MDS.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Myelodysplastic Syndrome: Overview of Diagnosis, Classification, and Treatment
    EP. 2: Clinical Insights into the COMMANDS Trial
    EP. 3: Lower-Risk MDS: How Do Practice Patterns Compare Worldwide?
    EP. 4: MEDALIST Trial: Luspatercept in Patients with Lower-Risk MDS
    Now Viewing
    EP. 5: Recent Updates for Second-Line Treatment Options in Lower-Risk MDS
    EP. 6: Clinical Implications of Recent Data on New Agents in Lower-Risk MDS
    EP. 7: Real-World Data for Luspatercept in Lower-Risk MDS
    EP. 8: Treatment Strategies and Sequencing in MDS
    EP. 9: Unmet Needs and Future of Lower-Risk MDS

    Related Content:

    Lower-Risk MDS: Current and Future Treatment StrategiesMoffitt Cancer CenterHematologic OncologyInsights
    CHMP Recommends Brentuximab Vedotin Plus ECADD for Newly Diagnosed Stage IIB/III/IV Hodgkin Lymphoma
    Retrospective Data Show Improved Efficacy but Higher Toxicity With Cilta-Cel vs Ide-Cel in R/R Myeloma
    The Future of CAR T-Cell Therapy in R/R DLBCL: Closing Reflections and Key Takeaways
    x